NASDAQ:HSDT

Helius Medical Technologies - HSDT Competitors

$0.53

-0.02 (-3.61%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.50
▼
$0.57
50-Day Range: $0.48
▼
$2.02
52-Week Range: $0.45
▼
$15.68

Volume: 6.69 million shs
Average Volume: 1.23 million shs
Market Capitalization: $2.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.00

HSDT vs. NUWE, KPRX, SPRC, VLON, THMO, AGRX, SXTC, GNCA, CGIX, and FWBI

Should you be buying Helius Medical Technologies stock or one of its competitors? The main competitors of Helius Medical Technologies include Nuwellis (NUWE), Kiora Pharmaceuticals (KPRX), SciSparc (SPRC), Vallon Pharmaceuticals (VLON), ThermoGenesis (THMO), Agile Therapeutics (AGRX), China SXT Pharmaceuticals (SXTC), Genocea Biosciences (GNCA), Cancer Genetics (CGIX), and First Wave BioPharma (FWBI). These companies are all part of the "medical" sector.

Helius Medical Technologies vs.

Helius Medical Technologies (NASDAQ:HSDT) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations.

: Helius Medical Technologies currently has a consensus target price of $20.00, suggesting a potential upside of 3,643.22%. Nuwellis has a consensus target price of $7.50, suggesting a potential upside of 983.35%. Given Helius Medical Technologies' higher possible upside, research analysts clearly believe Helius Medical Technologies is more favorable than Nuwellis.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Helius Medical Technologies
0 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
Nuwellis
0 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
3.00
: Helius Medical Technologies has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
: Nuwellis has a net margin of -240.83% compared to Helius Medical Technologies' net margin of -3,043.95%. Nuwellis' return on equity of -77.16% beat Helius Medical Technologies' return on equity.
Company Net Margins Return on Equity Return on Assets
Helius Medical Technologies -3,043.95% -240.53% -180.70%
Nuwellis -240.83% -77.16% -65.30%
: Nuwellis received 2 more outperform votes than Helius Medical Technologies when rated by MarketBeat users. However, 54.84% of users gave Helius Medical Technologies an outperform vote while only 52.78% of users gave Nuwellis an outperform vote.
Company Underperform Outperform
Helius Medical Technologies Outperform Votes
17
54.84%
Underperform Votes
14
45.16%
Nuwellis Outperform Votes
19
52.78%
Underperform Votes
17
47.22%
: Helius Medical Technologies has higher earnings, but lower revenue than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Helius Medical Technologies, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Helius Medical Technologies $520 thousand 3.90 -$18.13 million -$7.05 -0.08
Nuwellis $7.92 million 0.92 -$19.58 million -$1.99 -0.35
: 29.7% of Helius Medical Technologies shares are held by institutional investors. Comparatively, 18.2% of Nuwellis shares are held by institutional investors. 11.2% of Helius Medical Technologies shares are held by insiders. Comparatively, 0.9% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: In the previous week, Helius Medical Technologies had 4 more articles in the media than Nuwellis. MarketBeat recorded 11 mentions for Helius Medical Technologies and 7 mentions for Nuwellis. Nuwellis' average media sentiment score of 1.47 beat Helius Medical Technologies' score of 0.98 indicating that Nuwellis is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Helius Medical Technologies
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nuwellis
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Helius Medical Technologies	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuwellis	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Net Margins	Return on Equity	Return on Assets
Helius Medical Technologies	-3,043.95%	-240.53%	-180.70%
Nuwellis	-240.83%	-77.16%	-65.30%

Company	Underperform	Outperform
Helius Medical Technologies	Outperform Votes 17 54.84%	Underperform Votes 14 45.16%
Nuwellis	Outperform Votes 19 52.78%	Underperform Votes 17 47.22%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Helius Medical Technologies	$520 thousand	3.90	-$18.13 million	-$7.05	-0.08
Nuwellis	$7.92 million	0.92	-$19.58 million	-$1.99	-0.35

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Helius Medical Technologies	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuwellis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nuwellis beats Helius Medical Technologies on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSDT vs. The Competition

Export to Excel

Metric	Helius Medical Technologies	Electromedical equipment Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.03M	$3.74B	$4.41B	$6.38B
Dividend Yield	N/A	1.44%	7.26%	3.17%
P/E Ratio	-0.08	12.73	123.55	18.51
Price / Sales	3.90	39.27	2,950.75	128.88
Price / Cash	N/A	30.77	22.89	29.84
Price / Book	0.18	3.77	6.46	6.21
Net Income	-$18.13M	$133.75M	$166.90M	$239.70M
7 Day Performance	9.11%	6.84%	4.70%	4.54%
1 Month Performance	-50.07%	15.15%	10.80%	12.20%
1 Year Performance	-96.28%	-27.94%	-27.19%	-20.33%

Helius Medical Technologies Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUWE Nuwellis	2.1621 of 5 stars	$0.67 +1.5%	$7.50 +1,027.2%	-83.7%	$7.01M	$7.92M	-0.29	70	Positive News
KPRX Kiora Pharmaceuticals	2.5321 of 5 stars	$0.16 flat	$1.75 +1,029.0%	N/A	$2.03M	$10,000.00	-0.09	14	Analyst Downgrade High Trading Volume
SPRC SciSparc	1.1469 of 5 stars	$1.24 -0.8%	N/A	N/A	$1.29M	$1.99M	0.00	2	News Coverage Positive News Gap Up
VLON Vallon Pharmaceuticals	2.0463 of 5 stars	$0.40 +8.2%	$12.00 +2,937.2%	-89.1%	$2.69M	$100,000.00	-0.32	3	Gap Up
THMO ThermoGenesis	2.7113 of 5 stars	$0.22 flat	$6.00 +2,627.3%	-87.8%	$2.82M	$9.29M	-0.24	39
AGRX Agile Therapeutics	2.3737 of 5 stars	$0.63 -5.9%	$130.00 +20,388.6%	-98.7%	$2.88M	$4.10M	-0.02	28	Earnings Report Analyst Upgrade Gap Down
SXTC China SXT Pharmaceuticals	0 of 5 stars	$1.52 -5.0%	N/A	-93.1%	$3.09M	$2.60M	0.00	96
GNCA Genocea Biosciences	1.559 of 5 stars	$0.01 flat	$3.00 +27,172.7%	-99.4%	$646,000.00	$1.64M	-0.02	74
CGIX Cancer Genetics	0 of 5 stars	$0.79 -1.2%	N/A	N/A	$3.24M	N/A	0.00	N/A
FWBI First Wave BioPharma	2.2019 of 5 stars	$0.16 +6.8%	$8.50 +5,296.8%	N/A	$3.27M	N/A	0.00	17	Positive News

This page (NASDAQ:HSDT) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms